Resources

3 Resources for

zentiva

Subscribe to this listing via:
RSS
Email

BNET Resources

Sanofi strikes back in takeover battle for big Czech drug company: PRAGUE AFP — Czech-based generic drugs giant Zentiva was at the heart of a takeover tussle Wednesday after French group Sanofi-Aventis struck back with an offer countering a bid by local financial concern PPF. PPF, holding a 19.2 percent stake in Zentiva, which has substantial markets in Slovakia, Romania...; Tags: Agence France-Presse, analyst, Europe, FINANCE, Government, Investment, Prague, Sanofi-Aventis, Slovakia, SOFTWARE, Zentiva; Research articles 2008-06-18
Czech pharma giant buys Turkish peer: PRAGUE AFP — The Czech Republic's biggest pharmaceutical company, Zentiva, said Monday that it had agreed to buy 75 percent of Turkey's biggest drug company Eczacibasi Generic Pharmaceuticals for 460 million euros (606.7 million dollars). The Czech company, which already has plants in Slovakia and Romania, added that it...; Tags: Agence France-Presse, Prague, Turkey, Zentiva; Research articles 2007-03-05
Why Can't Sanofi Get That Zentiva Deal Done?: The M&A chess match going on between Sanofi-Aventis and Zentiva, a Czech Republic-based generic drug maker, is fascinating because it seems that the tiny Czech company is the one in a position of strength. Sanofi's bid was rejected by Zentiva on Wednesday. At first glance, it appears...; Tags: Crown, Zentiva, Sanofi, Balance Sheets, Sales Strategy, Mergers & Acquisitions, Investment, Financial Statements, Financial Accounting, Finance, Sales, Jim Edwards; Blog posts 2008-09-05

Additional Resources

Generic Drugs: Industry Snapshot: Mike Havrilla submits:Global Generic Drug Industry: Benchmark Comps Global Generic Drug Industry: Top 5 Companies by Market Cap Global Generic Drugs: Top 5 Companies by Stock Performance The accompanying tables provide a snapshot of my 38-company Global Generic Drug Index, which is rapidly consolidating amidst a flurry of recent M&A activity --...; Tags: Healthcare, Bentley Pharmaceuticals Inc., Barr Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Sanofi-Aventis; External links 2008-08-15
Should Sanofi-Aventis Buy Bristol Myers-Squibb?: Bristol-Myers Squibb CEO James Cornelius said in a recent earnings call that due to its healthy cash position it may be on the prowl for biotech acquisitions. That's ironic because it is looking more like BMS itself could be the company to be acquired, possibly by Sanofi-Aventis. ...; Tags: Sanofi-Aventis, CEO, BMS, Sanofi, Mergers & Acquisitions, Corporate Law, Biotechnology, Investment, Finance, Business Operations, Jim Edwards; Blog posts 2008-10-27

The Sanofi-Bristol-Myers Squibb Worst-Case Scenario: Bristol-Myers Squibb seems to live permanently with the rumor that it is about to be acquired by Sanofi-Aventis. The last time this old saw popped up was in the fall of 2008. At that time BNET said "Perhaps itâ€™s time to consummate this relationship." This time around,...; Tags: Pfizer Inc., BMS, Plavix, Sanofi, Research & Development, Federal Government, Sales Strategy, Asset Management, Business Operations, Government, Sales, Operational Planning, Jim Edwards; Blog posts 2009-02-03
Sanofi CEO Viehbacher Wants More Cuts; Drug Reps' Necks on the Block: Sanofi-Aventis's Q4 earnings call tomorrow could set the stage for a dramatic few days at the company, according to Bloomberg, as CEO Chris Viehbacher told analysts and his staff that Sanofi needs to cut operating costs and possibly buy a small or midsize firm. Viehbacher wants to get $1.3 billion...; Tags: Revenue, Layoff, Pfizer Inc., Stock, Bloomberg L.P., CEO, Sanofi, Operational Accounting, Workforce Management, Finance, Human Resources, Jim Edwards; Blog posts 2009-02-10
Sanofi Q4: No Nasty Surprises, But Viehbacher Is Focused on Sales Productivity Ratios: There were no nasty surprises in Sanofi-Aventis's Q4 results. Yesterday, BNET had suggested that CEO Chris Viehbacher's desire to cut $1.3 billion in operating costs would fall upon sales reps, whose jobs would be axed. We also noted that, dollar for dollar (or euro for euro, in...; Tags: Sanofi-Aventis, CEO, Sales Strategy, Sales Force Management, Workforce Management, Sales, Human Resources, Jim Edwards; Blog posts 2009-02-11
Sanofi and Teva raided in EU antitrust probe: Sanofi-Aventis, the Paris-based pharmaceutical group, and Israel's Teva, the world's largest generic drugs producer, have been raided by European competition officials in a fresh probe into suspected antitrust breaches believed to have occurred in France. The European Commission said "surprise inspections" had begun on Tuesday at the premises of a...; Tags: European Commission, Pharmaceutical Company, Commission, Sanofi-Aventis; News items 2009-10-06
Scale of generic drug raids in France points to wider investigation: The breadth of the European Commission's antitrust probe into the generic industry launched this week suggests it extends beyond a single deal and explores practices across the sector in France, industry experts said yesterday.Sanofi-Aventis, Ratio-pharm, Teva, Ranbaxy and Novartis all confirmed that their French offices had been raided by...; Tags: Commission, Antitrust, France, European Union, Raid, Corporate Law, Sales Force Management, Security, Business Operations, Sales, Company News, European Union Government, Government News, Monopolies & Antitrust, Regulation of Business, Financial Times; External links 2009-10-07